<format type="yaml">{report_id: string, report_date: date, patient_details: {patient_id: string, age_at_reaction: number optional, gender: string, relevant_history: list[string]}, suspected_drugs: list[{drug_name: string, drug_class: string optional, dosage: string, route_of_administration: string, start_date: date, end_date: date optional, indication_for_use: string}], adverse_reactions: list[{symptom_name: string, onset_date: date, severity: string, outcome: string, intervention_required: boolean, intervention_details: string optional}], causality_assessment: {naranjo_score: number optional, assessment_conclusion: string, dechallenge_rechallenge: string}, reporting_facility: string, reporter_type: string, notes: string optional}</format> <data>PHARMACOVIGILANCE CASE REPORT - CONFIDENTIAL
Report Identifier: ADR-2025-383
Date of Submission: 2025-08-12

This report was submitted by a Pharmacist from Obrien Group Medical Center concerning patient ANON-PX-9376. The subject is a 59-year-old other with a significant medical history including atrial fibrillation, anxiety. The facility's standard operating procedure for ADR reporting was followed, and all patient data has been anonymized. The patient chart was reviewed for comorbidities. 

Current medication review revealed the following suspected agent(s): Levothyroxine (Thyroid hormone) administered via the Intravenous route at a dosage of 42mg, initiated on 2025-07-29 for Hypothyroidism with the course ongoing; Omeprazole administered via the Topical route at a dosage of 315mg, initiated on 2025-07-29 for Gastroesophageal reflux disease with the course ongoing.

On approximately 2025-07-31, the patient began to manifest an adverse event. The primary symptoms noted in the clinical log were Diarrhea, Headache, Nausea. The Diarrhea was classified as Life-threatening in severity. This necessitated clinical intervention. The documented action was: Prescribed government and advised chance. The current patient status regarding this symptom is 'Recovered'. The Headache was classified as Life-threatening in severity. This necessitated clinical intervention. The current patient status regarding this symptom is 'Unknown'. The Nausea was classified as Moderate in severity. No specific therapeutic intervention was required. The current patient status regarding this symptom is 'Not Recovered'. 

CAUSALITY ASSESSMENT:
An evaluation of causality was performed. A Naranjo score of 5 was calculated, The assessment concluded the relationship was 'Probable'. Dechallenge/Rechallenge status was noted as: 'Not applicable'. The on-site pharmacist concurred with the assessment during a routine case review. 

Reporter's Narrative Summary: Picture herself available window might. Congress career baby.</data>
report_id: ADR-2025-383
report_date: '2025-08-12'
patient_details:
  patient_id: ANON-PX-9376
  gender: Other
  relevant_history:
  - atrial fibrillation
  - anxiety
  age_at_reaction: 59
suspected_drugs:
- drug_name: Levothyroxine
  dosage: 42mg
  route_of_administration: Intravenous
  start_date: '2025-07-29'
  indication_for_use: Hypothyroidism
  drug_class: Thyroid hormone
- drug_name: Omeprazole
  dosage: 315mg
  route_of_administration: Topical
  start_date: '2025-07-29'
  indication_for_use: Gastroesophageal reflux disease
adverse_reactions:
- symptom_name: Diarrhea
  onset_date: '2025-07-31'
  severity: Life-threatening
  outcome: Recovered
  intervention_required: true
  intervention_details: Prescribed government and advised chance.
- symptom_name: Headache
  onset_date: '2025-07-31'
  severity: Life-threatening
  outcome: Unknown
  intervention_required: true
- symptom_name: Nausea
  onset_date: '2025-07-31'
  severity: Moderate
  outcome: Not Recovered
  intervention_required: false
causality_assessment:
  assessment_conclusion: Probable
  dechallenge_rechallenge: Not applicable
  naranjo_score: 5
reporting_facility: Obrien Group Medical Center
reporter_type: Pharmacist
notes: Picture herself available window might. Congress career baby.
